



Flexion Therapeutics, Inc.
 Investor Relations Department
 10 Mall Road
 Suite 301
 Burlington, MA 01803
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

Last Trade:	24.81
Trade Time:	12:08 PM ET Feb 22, 2018
Change:	0.23 ↑ (+0.936%)
Day Range	24.59 - 25.27
52-Week Range	16.51 - 32.25
Volume	279,075

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 14, 2018*
[Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference](#)
- Feb 2, 2018*
[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Jan 8, 2018*
[Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\)](#)
- Dec 18, 2017*
[Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Osteoarthritis of the Shoulder and Hip](#)
- Dec 13, 2017*
[Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee](#)

Upcoming Events [\[View all \]](#)

- Mar 6, 2018 8:05 AM ET*
[Raymond James 39th Annual Institutional Investors Conference](#)
- Financials [\[View all \]](#)**
- [Third Quarter Financial Results](#)
- Mar 10, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)